{"entity":{"id":"nct05978284","kind":"trial","name":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","aka":[],"tldr":"A phase 1/2 trial of ZG006 in small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.","summary":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT05978284 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 54 participants planned, started 2023-10-27 and due to reach its primary completion in 2026-09. Interventions recorded: ZG006. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05978284","url":"https://clinicaltrials.gov/study/NCT05978284"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["zg006"],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05978284","phase":"1/2","setting":"A Phase 1/2 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","enrolled":54,"outcomes":[]},"route":"/trials/nct05978284/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}]}}